Vimian Group AB (publ) VIMIAN
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold; consider adding 10-20% after Q1 confirmation.
Core animal health operations and cash flow development look robust, while MedTech turnaround and management stability still require confirmation.
The market reacted positively to the strong organic growth and improved cash flow, although execution risks around MedTech remain.
HOLD is the call. Positive is the market mood. Medium risk means some things can go wrong.
Latest change
- 23 Oct 2026 — Report showed strong organic growth and improved cash flow which drove positive share reaction.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Vimian Group AB (publ) is a global animal health group operating across Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company grows through organic initiatives and acquisitions, but near-term uncertainty is elevated due to MedTech weakness and ongoing management changes.
Bull case
Continued double-digit organic growth and stable EBITA margin, with clear improvement in MedTech, could support a higher valuation if cash flow normalises.
Bear case
Weak cash conversion and rising working capital combined with higher net debt may increase balance sheet focus and limit upside despite good earnings growth.
Why this signal
Core animal health operations and cash flow development look robust, while MedTech turnaround and management stability still require confirmation.
Recent news
Q3 report showed revenue of EUR 120.3 m with 11 % organic growth and adjusted EBITA margin of 24.3 %. Operating cash flow strengthened to EUR 22.6 m and net debt fell to EUR 262.4 m. Norfolk Medical Products was acquired and Nordea plus ABG raised price targets to SEK 45.